Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3C3 | Q8NEB9 | 16/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.40 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19259445 | 1.00 | PIK3C3 (0.43) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL19259517 | 0.88 | PIK3C3 (0.45) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL24156689 | 0.84 | PIK3C3 (0.54) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL19259405 | 0.84 | PIK3C3 (0.54) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL19259511 | 0.84 | PIK3C3 (0.54) | PIK3C3PDCD1CD274ATRCHEK1 | |
| SCHEMBL19276388 | 0.81 | PIK3C3 (0.52) | PIK3C3PDCD1CD274 | |
| SCHEMBL19276389 | 0.81 | PIK3C3 (0.52) | PIK3C3PDCD1CD274 | |
| SCHEMBL19259449 | 0.81 | PIK3C3 (0.53) | PIK3C3 | |
| SCHEMBL19276422 | 0.81 | PIK3C3 (0.53) | PIK3C3 | |
| SCHEMBL19259447 | 0.80 | PIK3C3 (0.39) | PIK3C3PDCD1CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963963-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2024-04-23 | — | — | US | disclosed |
| US-20240050439-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Spring Bioscience AB (SE) | 2024-02-15 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2023-07-27 | — | — | US | disclosed |
| CN-116462674-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116444510-A | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-111108102-B | Morpholinyl pyridone compounds | 思普瑞特生物科学公司 | 2023-04-28 | — | — | CN | disclosed |
| US-11633403-B2 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2023-04-25 | — | — | US | disclosed |
| US-11560374-B2 | Morpholinylpyridone compounds | SPRINT BIOSCIENCE AB (SE) | 2023-01-24 | — | — | US | disclosed |
| EP-3416945-B1 | 6-ARYL-4-(MORPHOLIN-4-YL)-1H-PYRIDIN-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| CN-111108102-A | Morpholinopyridone compounds | 思普瑞特生物科学公司 | 2020-05-05 | — | — | CN | disclosed |
| WO-2019038390-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019038390-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | SPRINT BIOSCIENCE AB (SE) | 2019-02-28 | — | — | WO | disclosed |
| EP-3416945-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Sprint Bioscience AB (SE) | 2018-12-26 | — | — | EP | disclosed |
| EP-3416957-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Sprint Bioscience AB (SE) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017140843-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140841-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140843-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140841-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560374-B2 | Morpholinylpyridone compounds | MAP1B, RRP12, MYT1 | PIK3C3 3743/4885PDCD1 594/4885CD274 1041/4885 |
| US-20230234949-A1 | MORPHOLINYLPYRIDONE COMPOUNDS | MAP1B, RRP12, MYT1 | PIK3C3 3821/4885PDCD1 484/4885CD274 890/4885 |
| US-11963963-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | CDK6, IL6, CDK4 | PIK3C3 4621/4885PDCD1 1498/4885CD274 2397/4885 |
| US-11633403-B2 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | PYCR1, GPR119, IL6 | PIK3C3 4453/4885PDCD1 278/4885CD274 1537/4885 |
| US-20240050439-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | PYCR1, GPR119, CDK6 | PIK3C3 4489/4885PDCD1 289/4885CD274 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.